Cargando…
Targeting histone deacetyalses in the treatment of B- and T-cell malignancies
HDAC inhibitors (HDACI) are now emerging as one of the most promising new classes of drugs for the treatment of select forms of non-Hodgkin’s lymphoma (NHL). They are particularly active in T-cell lymphomas, possibly hodgkin’s lymphoma and indolent B cell lymphomas. Presently, two of these agents, v...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003796/ https://www.ncbi.nlm.nih.gov/pubmed/21132350 http://dx.doi.org/10.1007/s10637-010-9591-3 |